INTIBIA Pivotal Study
Study Details
Study Description
Brief Summary
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
All eligible subjects will be implanted with the INTIBIA device. Subjects will be randomized to either INTIBIA therapeutic or INTIBIA non-therapeutic in a 2:1 ratio for the first 3 months of the study, at which point all subjects will receive therapeutic stimulation. Subjects will complete voiding diaries and questionnaires at Baseline and prior to each follow-up visit, which will occur at Months 3, 6, 12, and 24. Subjects will be offered to keep the device or have it explanted at the end of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: INTIBIA Therapeutic Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study. |
Device: INTIBIA Therapeutic
INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
|
| Experimental: INTIBIA Non-Therapeutic Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study. |
Device: INTIBIA Non-Therapeutic
INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
|
Outcome Measures
Primary Outcome Measures
- Response Rate [3 Months]
≥50% reduction in UUI episodes between INTIBIA therapeutic and INTIBIA non-therapeutic
- Response Rate [12 Months]
≥50% reduction in UUUI episodes in the INTIBIA therapeutic group
Secondary Outcome Measures
- Urgency Score [3 Months]
Change in mean urgency score relative to baseline on a scale of 0 (no urgency) to 4 (urge incontinence)
- Daily Voids [3 Months]
Change in mean number of daily voids relative to baseline
Other Outcome Measures
- Response Rate [6 Months]
≥50% reduction in UUUI episodes in the INTIBIA therapeutic group
- Response Rate [3, 6, and 12 Months]
≥50% reduction in number of voids or a return to normal voiding frequency (< 8 voids/day)
- Daily Voids [6 and 12 Months]
Change in mean number of daily voids relative to baseline
- Urgency Score [6 and 12 Months]
Change in mean urgency score relative to baseline on a scale of 0 (no urgency) to 4 (urge incontinence)
- International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form [3, 6, and 12 Months]
Change in ICIQ-UI SF questionnaire total score compared to baseline. Scoring 0 (best outcome) - 21 (worst outcome)
- OverActive Bladder questionnaire - Short Form [3, 6, and 12 Months]
Change in the OABq-SF questionnaire total score compared to baseline. Scoring 1 (best) - 6 (worst) on 19 questions.
- Dry [3, 6, and 12 Months]
The proportion of dry subjects, defined as those with 0 incontinence episodes associated with urgency as captured on the 72-hour voiding diary
- Patient's Global Impression of Improvement Questionnaire [3, 6, and 12 Months]
The proportion of subjects reporting "much better" or "very much better" on the Patient Global Impression of Improvement (PGI-I) questionnaire
- Surgical Satisfaction Questionnaire (SSQ-8) [3 Months]
Surgical Satisfaction Questionnaire (SSQ-8)
- EQ-5D-5L Questionnaire [3, 6, and 12 Months]
Change in the EQ-5D-5L index score compared to baseline, on a 1-5 scale with 1 being the best outcome and 5 being the worst outcome. VAS scale measures overall health with 0 being the worst outcome and 100 being the best outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women or men 22-80 years of age
-
Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period
-
Greater than or equal to 6-month history of UUI diagnosis
-
Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management)
-
Willing to abstain from OAB medications for the duration of the study
-
Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires
-
Ambulatory and able to use the toilet independently and without difficulty
-
Willing and capable of providing informed consent
-
Willing and able to complete all procedures and follow-up visits indicated in the protocol
Exclusion Criteria:
-
Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire
-
Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year
-
Have post-void residual urine volume >30% of total voided volume
-
Inadequate skin integrity or any evidence of an infection, edema or inflammation in either lower leg
-
Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject
-
Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS])
-
History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain)
-
An active implantable electronic device regardless of whether stimulation is ON or OFF
-
Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months
-
Any neurological condition that could interfere with normal bladder or tibial nerve function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia)
-
Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture)
-
Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula)
-
End stage renal failure, GFR < 35, or dialysis
-
History of pelvic cancer within the past two years
-
Pelvic organ prolapse at or beyond the hymenal ring
-
Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date
-
Diabetes with peripheral nerve compromise or uncontrolled diabetes
-
Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding
-
Current active or a chronic systemic infection
-
Condition requiring magnetic resonance imaging (MRI) of lower leg
-
Condition requiring diathermy
-
Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane
-
Allergy to local anesthetic or adhesives
-
Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications)
-
Enrolled in another investigational or interventional device or drug trial over the study period
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Southeastern Urogynecology & Pelvic Surgery | Moultrie | Georgia | United States | 31768 |
| 2 | Rosemark WomenCare Specialists | Idaho Falls | Idaho | United States | 83402 |
| 3 | Cypress Medical Research Center, LLC | Wichita | Kansas | United States | 67226 |
| 4 | Advanced Urogynecology of Michigan | Dearborn | Michigan | United States | 48124 |
| 5 | Wake Forest University | Winston-Salem | North Carolina | United States | 27103 |
| 6 | Houston Metro Urology | Houston | Texas | United States | 77027 |
Sponsors and Collaborators
- Coloplast A/S
Investigators
- Principal Investigator: Catherine Matthews, MD, Wake Forest University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IU024